The success of this approach has been demonstrated by the recent launch of Kynos Therapeutics, an Edinburgh-based company devoted to the application of KMO inhibition in the therapeutic management of pancreatitis [110,334,335]. This evidence concerns the gene KMO and pancreatitis.